Scott has made over 8 trades of the Harpoon Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 10,500 units of HARP stock worth 241,605$ on 11 January 2018.
The largest trade he's ever made was buying 62,500 units of Harpoon Therapeutics stock on 28 June 2016 worth over 50,000$. On average, Scott trades about 3,745 units every 14 days since 2016. As of 11 January 2018 he still owns at least 60,216 units of Harpoon Therapeutics stock.
You can see the complete history of Mr. Myers stock trades at the bottom of the page.
Scott D. Myers serves as Independent Director of the Company. Mr. Myers has served as Chairman of the board of directors of Rainier Therapeutics, Inc., a private oncology biotechnology company since June 2018, and served as Chief Executive Officer from September 2018 to December 2019. Prior to Rainier, Mr. Myers served as Chief Executive Officer, President and Director for Cascadian Therapeutics, Inc., an oncology company, from April 2016 through its acquisition by Seattle Genetics in March 2018. Prior to Cascadian, Mr. Myers served as the Chief Executive Officer of Aerocrine AB, a Swedish medical device company from September 2011 through its acquisition by Circassia Pharmaceuticals plc in July 2015. Mr. Myers also serves on the Board of Directors of Selecta Biosciences (Nasdaq: SELB), a clinical-stage biotechnology company. Mr. Myers served as a director for Orexo AB, a pharmaceutical company, from April 2012 to April 2014.
As the Independent Director of Harpoon Therapeutics, the total compensation of Scott Myers at Harpoon Therapeutics is 134,343$. There are 9 executives at Harpoon Therapeutics getting paid more, with Gerald McMahon having the highest compensation of 1,793,260$.
Scott Myers is 54, he's been the Independent Director of Harpoon Therapeutics since 2018. There are 7 older and 5 younger executives at Harpoon Therapeutics. The oldest executive at Harpoon Therapeutics, Inc. is Gerald McMahon, 65, who is the President, Chief Executive Officer, Director.
Scott's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES, 2100 POWELL STREET, SUITE 720, EMERYVILLE, CA, 94608.
Over the last 6 years, insiders at Harpoon Therapeutics have traded over 62,512,704$ worth of Harpoon Therapeutics stock and bought 26,100,850 units worth 525,945,967$ . The most active insiders traders include & Co., Inc.Merck Sharp & Do...、Ronald Hunt、Bioscience Plc Arix Bioscie.... On average, Harpoon Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of 9,736,866$. The most recent stock trade was executed by & Co., Inc.Merck Sharp & Do... on 11 March 2024, trading 21,397,205 units of HARP stock currently worth 492,135,715$.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Harpoon Therapeutics executives and other stock owners filed with the SEC include: